Stevanato Group S.p.A. (STVN)

-0.15% (1D)

Market Cap	5.54B
Revenue (ttm)	1.14B
Net Income (ttm)	121.94M
Shares Out	272.90M
EPS (ttm)	0.45
PE Ratio	45.58
Forward PE	35.18
Dividend	$0.06 (0.29%)
Ex-Dividend Date	Jun 4, 2024

Volume	209,138
Open	20.18
Previous Close	20.32
Day's Range	20.12 - 20.46
52-Week Range	16.56 - 32.98
Beta	0.60
Analysts	Buy
Price Target	26.93 (+32.73%)
Earnings Date	Mar 6, 2025

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass f...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,521
• Stock Exchange: NYSE
• Ticker Symbol: STVN
• Website: https://www.stevanatogroup.com

Financial Performance

In 2024, Stevanato Group's revenue was 1.10 billion, an increase of 1.72% compared to the previous year's 1.09 billion. Earnings were 117.78 million, a decrease of -19.13%.

Financial numbers in EUR

Analyst Forecast

According to 7 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $26.93, which is an increase of 32.73% from the latest price.

Price Target

$26.93

(32.73% upside)

Analyst Consensus: Buy